References
- Moffat AC, Osselton MD, Widdop B, Clarke EGC. Clarke's Analysis of Drugs and Poisons: in Pharmaceuticals, Body Fluids and Postmortem Material. 3rd ed. London: Pharmaceutical Press; 2004.
- Ellenhorn MJ. Ellenhorn's Medical Toxicology: Diagnosis and Treatment of Human Poisoning. 2nd ed. Baltimore, MD: Williams & Wilkins; 1997.
- Boldt J, Suttner S. Combined use of ultra-short acting beta-blocker esmolol and intravenous phosphodiesterase 3 inhibitor enoximone. Expert Opin Pharmacother 2007; 8(13):2135–2147.
- Varpula T, Rapola J, Sallisalmi M, Kurola J. Treatment of serious calcium channel blocker overdose with levosimendan, a calcium sensitizer. Anesth Analg 2009 Mar; 108(3):790–792.
- Ujhelyi MR, Robert S. Pharmacokinetic aspects of digoxin-specific Fab therapy in the management of digitalis toxicity. Clin Pharmacokinet 1995 Jun; 28(6):483–493.
- DeVore KJ, Hobbs RA. Plasma digoxin concentration fluctuations associated with timing of plasma sampling and amiodarone administration. Pharmacotherapy 2007; 27(3):472–475.
- Fenner KS, Troutman MD, Kempshall S, Cook JA, Ware JA, Smith DA, Lee CA. Drug–drug interactions mediated through P-glycoprotein: clinical relevance and in vitro–in vivo correlation using digoxin as a probe drug. Clin Pharmacol Ther 2009 Feb; 85(2):173–181.
- Quaife EJ, Banner W Jr., Vernon DD, Christensen DW. Failure of CAVH to remove digoxin-Fab complex in piglets. J Toxicol Clin Toxicol 1990; 28(1):61–68.